| 1 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung‐Jue Bang, Eric Van Cutsem, Andrea Feyereislova et al. · The Lancet
Open access |
Aug 2010 |
7,405 |
| 2 |
Comprehensive molecular characterization of gastric adenocarcinoma
Adam Joel Bass et al. · Nature
Open access258 authors |
23 Jul 2014 |
6,680 |
| 3 |
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
Daniel J. Klionsky et al. · Autophagy
Open access2,467 authors |
2 Jan 2016 |
6,023 |
| 4 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann‐Lii Cheng et al. · The Lancet Oncology
|
18 Dec 2008 |
5,881 |
| 5 |
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda et al. · Science Translational Medicine
Open access |
19 Feb 2014 |
5,211 |
| 6 |
Genetic effects on gene expression across human tissues
François Aguet et al. · Nature
Open access250 authors |
10 Oct 2017 |
4,762 |
| 7 |
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al. · New England Journal of Medicine
Open access |
18 May 2014 |
4,731 |
| 8 |
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al. · The Lancet
Open access |
20 Apr 2017 |
4,384 |
| 9 |
The repertoire of mutational signatures in human cancer
Ludmil B. Alexandrov et al. · Nature
Open access1,384 authors |
5 Feb 2020 |
3,854 |
| 10 |
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt, Ronald de Wit, David J. Vaughn et al. · New England Journal of Medicine
Open access |
17 Feb 2017 |
3,457 |
| 11 |
Pan-cancer analysis of whole genomes
Lauri A. Aaltonen et al. · Nature
Open access1,324 authors |
5 Feb 2020 |
3,360 |
| 12 |
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
Thierry André et al. · New England Journal of Medicine
Open access |
2 Dec 2020 |
3,130 |
| 13 |
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Tomasz M. Beer et al. · New England Journal of Medicine
Open access |
Jun 2014 |
3,076 |
| 14 |
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
Matthew David Hellmann et al. · New England Journal of Medicine
Open access |
28 Sep 2019 |
2,901 |
| 15 |
Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations
Jimmy Z. Liu et al. · Nature Genetics
Open access |
20 Jul 2015 |
2,805 |
| 16 |
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1
Daniel J. Klionsky et al. · Autophagy
Open access2,930 authors |
2 Jan 2021 |
2,743 |
| 17 |
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Shanu Modi et al. · New England Journal of Medicine
Open access |
5 Jun 2022 |
2,702 |
| 18 |
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Shiv Kumar Sarin et al. · Hepatology International
Open access |
13 Nov 2015 |
2,603 |
| 19 |
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Robert John Motzer et al. · New England Journal of Medicine
Open access |
16 Feb 2019 |
2,590 |
| 20 |
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
José Baselga, Javier Cortés, Sung‐Bae Kim et al. · New England Journal of Medicine
Open access |
7 Dec 2011 |
2,559 |
| 21 |
Comprehensive genomic profiles of small cell lung cancer
Julie George et al. · Nature
Open access |
10 Jul 2015 |
2,448 |
| 22 |
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
Serena Nik‐Zainal et al. · Nature
Open access |
29 Apr 2016 |
2,395 |
| 23 |
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Ghassan K. Abou‐Alfa et al. · New England Journal of Medicine
Open access |
4 Jul 2018 |
2,386 |
| 24 |
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon‐Koo Kang et al. · The Lancet
Open access |
12 Oct 2017 |
2,317 |
| 25 |
Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)
Waleed A. Alhazzani et al. · Intensive Care Medicine
Open access |
28 Mar 2020 |
2,204 |
| 26 |
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain, José Baselga, Sung‐Bae Kim et al. · New England Journal of Medicine
Open access |
18 Feb 2015 |
2,183 |
| 27 |
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
Pasi Antero Janne, James Chih‐Hsin Yang, Dong‐Wan Kim et al. · New England Journal of Medicine
Open access |
29 Apr 2015 |
2,135 |
| 28 |
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Martin Jean Schlumberger, Makoto Tahara, Lori J. Wirth et al. · New England Journal of Medicine
Open access |
11 Feb 2015 |
2,109 |
| 29 |
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al. · New England Journal of Medicine
Open access |
11 Dec 2019 |
2,026 |
| 30 |
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Norikazu Masuda et al. · New England Journal of Medicine
Open access |
31 May 2017 |
1,947 |
| 31 |
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Richard S. Finn et al. · Journal of Clinical Oncology
|
2 Dec 2019 |
1,842 |
| 32 |
Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer
Yi-Long Lung Cancer Wu et al. · New England Journal of Medicine
Open access |
19 Sep 2020 |
1,809 |
| 33 |
KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong et al. · New England Journal of Medicine
Open access |
20 Sep 2020 |
1,743 |
| 34 |
The Effectiveness and Risks of Bariatric Surgery
Su‐Hsin Chang, Carolyn R. T. Stoll, Ji‐Hyun Song et al. · JAMA Surgery
Open access |
18 Dec 2013 |
1,688 |
| 35 |
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew Xiuxuan Zhu et al. · The Lancet Oncology
|
18 Jan 2019 |
1,680 |
| 36 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
Jong‐Mu Sun et al. · The Lancet
Open access |
Aug 2021 |
1,679 |
| 37 |
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Marcia S. Brose, Christopher M. Nutting, Barbara Jarząb et al. · The Lancet
Open access |
23 Apr 2014 |
1,665 |
| 38 |
Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease
Jeong‐Hoon Lee, Donghee Kim, Hwa Jung Kim et al. · Digestive and Liver Disease
|
19 Sep 2009 |
1,664 |
| 39 |
Association analysis identifies 65 new breast cancer risk loci
Kyriaki Michailidou et al. · Nature
Open access362 authors |
20 Oct 2017 |
1,602 |
| 40 |
Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Jason Phua, Li Weng, Lowell Ling et al. · The Lancet Respiratory Medicine
Open access |
6 Apr 2020 |
1,580 |
| 41 |
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
Ghassan K. Abou‐Alfa et al. · NEJM Evidence
Open access |
6 Jun 2022 |
1,534 |
| 42 |
International Consensus Diagnostic Criteria for Autoimmune Pancreatitis
Tooru Shimosegawa, Suresh T. Chari, Luca Frulloni et al. · Pancreas
|
16 Mar 2011 |
1,529 |
| 43 |
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Scott Kopetz et al. · New England Journal of Medicine
Open access |
30 Sep 2019 |
1,500 |
| 44 |
Diagnostic Performance of Noninvasive Fractional Flow Reserve Derived From Coronary Computed Tomography Angiography in Suspected Coronary Artery Disease
Bjarne Linde Nørgaard, Jonathon A Leipsic, Sara Gaur et al. · Journal of the American College of Cardiology
Open access |
31 Jan 2014 |
1,498 |
| 45 |
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis
Christoph David Stettler et al. · The Lancet
|
Sep 2007 |
1,432 |
| 46 |
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D. Demetri et al. · The Lancet
Open access |
21 Nov 2012 |
1,428 |
| 47 |
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
Kohei Shitara, Yung‐Jue Bang, Satoru Iwasa et al. · New England Journal of Medicine
Open access |
29 May 2020 |
1,352 |
| 48 |
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara et al. · The Lancet
Open access158 authors |
4 Jun 2018 |
1,338 |
| 49 |
Deep Learning in Medical Imaging: General Overview
June‐Goo Lee, Sanghoon Jun, Young-Won Cho et al. · Korean Journal of Radiology
Open access |
2017 |
1,298 |
| 50 |
Intertumoral Heterogeneity within Medulloblastoma Subgroups
Florence M.G. Cavalli et al. · Cancer Cell
Open access |
Jun 2017 |
1,290 |